Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 7.34M P/E - EPS this Y 19.70% Ern Qtrly Grth -
Income -12.19M Forward P/E -0.74 EPS next Y 59.90% 50D Avg Chg -7.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -22.00%
Dividend N/A Price/Book 4.90 EPS next 5Y - 52W High Chg -62.00%
Recommedations 2.30 Quick Ratio 4.89 Shares Outstanding 6.40M 52W Low Chg 23.00%
Insider Own 1.80% ROA -104.18% Shares Float 6.29M Beta 1.30
Inst Own 4.43% ROE -320.96% Shares Shorted/Prior 146.73K/318.89K Price 0.25
Gross Margin - Profit Margin - Avg. Volume 2,426,959 Target Price 7.50
Oper. Margin - Earnings Date Nov 12 Volume 875,571 Change -10.58%
About Adial Pharmaceuticals, Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Adial Pharmaceuticals, Inc News
11/14/24 Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
11/14/24 EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
11/13/24 Adial Pharmaceuticals Reports Third Quarter 2024 Financial ResultsΒ and Provides Business Update
11/05/24 Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
08:00 AM Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
10/17/24 Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
10/17/24 EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate
10/15/24 Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery
09/19/24 Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
09/04/24 Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
08/13/24 Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04
08/13/24 EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder
08/07/24 Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
08/07/24 EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4
07/31/24 Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
07:30 AM Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
07:00 AM EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder
06/20/24 Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
06/20/24 EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
ADIL Chatroom

User Image Yuyotech Posted - 1 day ago

$ADIL lmao 25’s the number

User Image Nakuldesai Posted - 1 day ago

$ADIL this will not move with any news.

User Image Hallochen Posted - 2 days ago

$QLGN $ADIL $NDRA $ELAB πŸ”₯πŸ”₯πŸ”₯

User Image Zebediah3 Posted - 2 days ago

$ADIL 😴

User Image Kkrie616 Posted - 3 days ago

$ADIL

User Image Kkrie616 Posted - 3 days ago

$ADIL Financial Position: Adial’s financial statements explicitly express substantial doubt about the company’s ability to continue as a going concern without securing additional funding. Adial reported a net loss of $11.13 million for the first nine months of 2024, up from $5.1 million in the same period of 2023, indicating increasing operating costs. Cash and cash equivalents increased to $5.2 million as of September 30, 2024, from $2.8 million at year-end 2023, primarily due to capital-raising activities. Significant accumulated deficit ($79.9 million) and ongoing cash burn raise concerns about the company’s ability to fund operations without securing additional capital. Strengths: Clear progress in clinical development with FDA-aligned endpoints and ongoing regulatory discussions. Potential for AD04 to expand into other markets, such as opioid use disorder, obesity, and smoking cessation. Recent capital inflows show the company’s ability to raise funds, albeit temporarily. Thoghts?

User Image Hallochen Posted - 4 days ago

$QLGN $ADIL BUY BUY BUY πŸš€πŸš€πŸš€πŸ’₯πŸ’₯πŸ’₯πŸ’₯πŸ’₯πŸ₯³πŸ₯³πŸ₯³πŸ₯³πŸ₯³πŸ₯³πŸ₯³

User Image Hallochen Posted - 4 days ago

$QLGN $ADIL $PRFX $SOAR $NCNC πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯

User Image Hallochen Posted - 4 days ago

$QLGN $ADIL $PRFX $SOAR $NCNC πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯

User Image Hallochen Posted - 4 days ago

$ADIL $QLGN $SONN $NDRA $SIDU It's getting slow. Soon to the Moon πŸ”₯πŸš€πŸš€πŸš€

User Image Hallochen Posted - 4 days ago

$ADIL Go, Go, Go πŸ’ͺ🏻πŸ’ͺ🏻πŸ’ͺ🏻πŸ₯³πŸ₯³πŸ₯³πŸ™πŸ™πŸ™

User Image Hallochen Posted - 4 days ago

$QLGN $ADIL I hope that we will see the great rise today. πŸ™πŸ™πŸ™

User Image Hallochen Posted - 4 days ago

$ADIL $NCNC $PRFX $SOARπŸ”₯πŸ”₯πŸ”₯

User Image Hallochen Posted - 4 days ago

$ADIL $ELAB $MYNZ $QLGN $SYRS New 8-K Form and 4 πŸ‘πŸ‘πŸ‘πŸ”₯πŸ”₯πŸ”₯πŸ™πŸ™πŸ™

User Image Hallochen Posted - 4 days ago

$ADIL Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effect Marks final study needed for the upcoming FDA meeting for the Phase 3 study design and ongoing partnership discussions

User Image sixfigures718 Posted - 5 days ago

$ADIL $ELAB $MYNZ $QLGN $SYRS

User Image Hallochen Posted - 5 days ago

$ADIL Adial Pharmaceuticals Advances AD04 with Promising Study ResultsCompany Announcements Adial Pharmaceuticals Advances

User Image Hallochen Posted - 5 days ago

$ADIL $QLGN CEO please GOOD NEWS πŸ™πŸ™πŸ™

User Image Nakuldesai Posted - 5 days ago

$ADIL these idiots keep on diluting

User Image Happy_Analyzer Posted - 5 days ago

$ADIL n e e d m o r e g o o d n e w s ;)

User Image Hallochen Posted - 5 days ago

$ADIL $QLGN We need partnership news with Astra πŸ™πŸ™πŸ™

User Image Hallochen Posted - 5 days ago

$ADIL shit 😟😟😟

User Image Nakuldesai Posted - 5 days ago

$ADIL below 1 coming

User Image Hallochen Posted - 5 days ago

$ADIL πŸš€πŸš€πŸš€πŸ™πŸ™πŸ™πŸ₯³πŸ₯³πŸ₯³

User Image RedBossman Posted - 5 days ago

$ADIL alcohol kills. We need this company for America!

User Image Hallochen Posted - 5 days ago

$ADIL $QLGN $ELAB $SYRS $MYNZπŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯πŸ”₯

User Image Hallochen Posted - 5 days ago

$ADIL $CERO FDA NewsπŸ”₯πŸ”₯πŸ”₯

User Image Hallochen Posted - 5 days ago

$ADIL $VCNX $ATCH $KACL $MOND πŸ”₯πŸ”₯πŸ”₯πŸ’₯πŸ’₯πŸ’₯πŸ”₯πŸ”₯πŸ”₯

User Image Hallochen Posted - 5 days ago

$ADIL

User Image Hallochen Posted - 5 days ago

$ADIL $VCNX $QLGN Partnership messages would also be welcome πŸ™πŸ˜πŸ‘

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schuyler Kevin Director Director Sep 29 Buy 2.74 700 1,918 700 10/03/23